Sera Prognostics was founded to develop diagnostic tests for the early prediction of a woman’s individualized risk of premature birth, preeclampsia, and other pregnancy complications. Sera’s tests are designed to give women and their physicians the power and time to make a difference in maternal and newborn health with individualized treatment and care plans.
The company has completed Its landmark Proteomic Assessment of Preterm Risk (PAPR) clinical study that clinically validated the PreTRM test as highly predictive of preterm birth early in pregnancy. To read more about this study, and its subsequent publication, click here.
The company’s proteomic predictor of premature birth risk—the PreTRM® Test for Risk Management-became commercially available in the U.S. in early 2016.See more